Hormone therapy prescribing patterns in the united states

Obstetrics and Gynecology

Volumn 104, Issue 5, 2004, Pages 1042-1050

  Newton, Katherine M ^a   Beverly, Kevin ^a   Connelly, Maureen T ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HORMONE;

ADULT; AGED; ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH MAINTENANCE ORGANIZATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; AGE DISTRIBUTION; CLINICAL PRACTICE; DRUG UTILIZATION; ESTROGEN THERAPY; MIDDLE AGED; RISK ASSESSMENT; UTILIZATION REVIEW;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; UNITED STATES;

EID: 20144388214     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000143826.38439.af     Document Type: Article

References (38)

1. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
3. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
4. Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990;12:259-85.
5. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
6. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
7. Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M. Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol 1990;76:579-84.
8. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 1997;8:146-58.
9. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer [published erratum appears in J Natl Cancer Inst 1995;87:1416]. J Natl Cancer Inst 1995;87:1067-71.
10. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
12. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38.
13. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
15. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:366-8.
16. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
17. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
18. Platt R, Davis R, Finkelstein J, Go AS, Gurwitz JH, Roblin D, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf 2001;10:373-7.
19. Menopause core curriculum study guide. 2nd ed. Cleveland (OH): North American Menopause Society; 2002. p. 126.
20. A new conjugated estrogen. Med Lett Drugs Ther 1999;41:67-8.
21. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol 1986;123:174-84.
22. Diggle PJ, Heagerty P, Liang KY, Zeger SL. Analysis of longitudinal data. 2nd ed. New York (NY): Oxford University Press; 2002.
23. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-32.
24. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. Br Med J 2003;327:845-6.
25. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-9.
26. Avis NE, McKinlay SM. The Massachusetts Women's Health Study: an epidemiologic investigation of the menopause. J Am Med Womens Assoc 1995;50:45-9, 63.
27. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-79.
28. Centers for Disease Control and Prevention. Health maintenance organizations (HMOs) and enrollment, according to model type, geographic region, and Federal program: United States, selected years 1976-2002. Available at: . Retrieved September 9, 2004.
29. Buist DSM, LaCroix AZ, Brenneman S, Abbott T. A population-based osteoporosis screening program: who does not respond and what are the consequences? J Am Geriatr Soc 2004;52:1130-7.
30. Newton KM, LaCroix AZ. The association between body mass index and reinfarction and survival after first myocardial infarction in women. J Women's Health 1996;5:433-44.
31. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84.
32. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
33. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54.
34. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
35. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663-72.
36. Prempro/Premp full revised label. Wyeth Pharmaceuticals. Available at: . Retrieved September 9, 2004.
37. Premarin full revised label. Wyeth Pharmaceuticals. Available at: . Retrieved September 9, 2004.
38. Female population by age, race and Hispanic or Latino origin for the United States: 2000. United States Census. Available at: . Retrieved September 9, 2004.